In 2006, Daiichi Pure Chemicals Co., Ltd. was acquired by SEKISUI Chemical Co., Ltd. In April of 2008, SEKISUI Medical Co., Ltd. was established by merging this acquisition with the Medical Products Division of SEKISUI Chemical. Later that same year, XenoTech, LLC was acquired to add focused expertise on biotransformation and preclinical drug development to the growing range of diagnostics and pharmaceutical development products and services offered by SEKISUI Medical.
Over the past 10 years, SEKISUI XenoTech has been joined by many companies around the globe to evolve into the present-day SEKISUI Medical Co. As our family grows, we continuously evolve and challenge ourselves to “contribute to the realization of healthy and enriched lifestyles for all people” in both new and vested ways. Joining SEKISUI has helped us expand our offerings and reach to become a truly global contract research organization (CRO) with unparalleled experience in absorption, distribution, metabolism, and excretion (ADME); drug metabolism and pharmacokinetics (DMPK); and DDI, offering a comprehensive range of products and services to accelerate drug development from discovery through clinical support, including screening, radiolabeling, active pharmaceutical ingredient (API) manufacturing, in vitro ADME, toxicology and pharmacology, in vivo pre-clinical ADME, toxicology and quantitative whole body autoradiography (QWBA), metabolite ID and production, bioanalytical services, and consulting.
It has been a great first decade. We can’t wait to see what the next one brings!
Learn more about:
About the Authors
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback